16 active not recruiting, 12 recruiting, 4 completed, 4 terminated. 37 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 37 | Active not recruiting 16, Recruiting 12, Completed 4, Terminated 4, Withdrawn 1 |
| Phase 2 | 8 | Active not recruiting 4, Terminated 2, Completed 1, Recruiting 1 |
Follow Unresectable Malignant Solid Neoplasm: new trials by email Literature Review of Unresectable Malignant Solid Neoplasm trials Research Report on Unresectable Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 36 | 2026-10-06 | 2026-10-16 |
| STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma Aldesleukin, Biopsy, Biospecimen Collection - Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2025-12-05 | 2025-12-24 | |
| MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 42 | 2025-11-07 | 2026-09-24 |
| TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma TR-002 - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | University of California, Davis | 52 | 2025-11-07 | 2026-07-16 |
| Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors Azenosertib, Biopsy Procedure, Biospecimen Collection - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 48 | 2025-02-03 | 2026-10-27 |
| Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 66 | 2024-06-07 | 2026-08-24 |
| Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2023-11-08 | 2026-10-28 |
| Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 45 | 2023-08-10 | 2026-07-31 |
| Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 43 | 2023-07-06 | 2026-08-03 |
| Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 58 | 2022-10-05 | 2026-10-02 |
| Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 42 | 2022-08-02 | 2026-10-14 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-10-20 | 2026-09-10 |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer Dostarlimab, Niraparib, Biopsy - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Active not recruiting | University of Washington | 18 | 2021-10-18 | 2026-08-20 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 55 | 2021-05-21 | 2026-09-08 |
| CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001 - Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Terminated | University of Southern California | 2 | 2021-04-29 | 2026-04-17 |
| Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor Pembrolizumab, Pevonedistat - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2021-03-29 | 2022-12-27 |
| SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL Anti-TGF-beta Monoclonal Antibody SAR-439459, Cemiplimab - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Terminated | M.D. Anderson Cancer Center | 3 | 2021-02-09 | 2023-08-14 |
| Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 62 | 2020-09-01 | 2026-02-27 |
Showing 20 of 37. Sign in to see all of them.
Neoplasm Metastasis (34) · Pancreatic Neoplasms (7) · Breast Neoplasms (6) · Melanoma (5) · Colorectal Neoplasms (4) · Lung Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Carcinoma, Transitional Cell (2) · Carcinosarcoma (2) · Endometrial Neoplasms (2) · Hematologic Neoplasms (2) · Small Cell Lung Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2)
Neoplasms (36) · Neoplastic Processes (34) · Pathologic Processes (34) · Pathological Conditions, Signs and Symptoms (34) · Neoplasms by Site (21) · Digestive System Diseases (12) · Digestive System Neoplasms (12) · Skin Diseases (12) · Skin and Connective Tissue Diseases (12) · Neoplasms by Histologic Type (9) · Breast Diseases (8) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Pancreatic Diseases (7) · Neoplasms, Germ Cell and Embryonal (6)
Specimen Handling (24) · Biopsy (23) · Magnetic Resonance Spectroscopy (17) · trastuzumab deruxtecan (6) · X-Rays (5) · olaparib (4) · pembrolizumab (4) · Immunoglobulin G (3) · copanlisib (3) · CTLA-4 Antigen (2) · Cyclophosphamide (2) · Disulfides (2) · Ipilimumab (2) · Irinotecan (2) · Nivolumab (2)
National Cancer Institute (NCI) (25) · M.D. Anderson Cancer Center (4) · Mayo Clinic (3) · City of Hope Medical Center (1) · Klinikum Klagenfurt am Wörthersee (1) · University of California, Davis (1) · University of Southern California (1) · University of Washington (1)
United States (35) · Canada (3) · Austria (1)
Timothy A Yap (5) · A P Chen (1) · Andrew Davis (1) · Antoni Ribas (1) · Anwaar Saeed (1) · Brian A Costello (1) · Diana L Hanna, MD (1) · Diwakar Davar (1) · Ecaterina E Dumbrava (1) · Edward J Kim, MD, PhD (1) · Elizabeth K Lee (1) · Elizabeth M. Swisher (1) · Filipa Lynce (1) · Funda Meric-Bernstam (1) · Geoffrey I Shapiro (1)
PMID 35396812, PMID 37597578, PMID 37823909, PMID 38261444, PMID 38270822, PMID 41118283, PMID 42247927
UM1CA186709 (7), UM1CA186688 (6), UM1CA186689 (3), UM1CA186690 (3), UM1CA186644 (2), UM1CA186716 (2), P30CA006516 (1), P30CA014089 (1), P30CA015083 (1), P30CA033572 (1), P30CA093373 (1), P50CA127003 (1), R44CA272064 (1), U01CA062490 (1), U01CA069912 (1)